Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Other: 2017-2024

Historic Receivables - Other for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $8.3 million.

  • Crinetics Pharmaceuticals' Receivables - Other rose 87.96% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 87.96%. This contributed to the annual value of $8.3 million for FY2024, which is 172.37% up from last year.
  • Crinetics Pharmaceuticals' Receivables - Other amounted to $8.3 million in FY2024, which was up 172.37% from $3.1 million recorded in FY2023.
  • Crinetics Pharmaceuticals' Receivables - Other's 5-year high stood at $8.3 million during FY2024, with a 5-year trough of $113,000 in FY2020.
  • Moreover, its 3-year median value for Receivables - Other was $3.1 million (2023), whereas its average is $4.2 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first crashed by 49.55% in 2020, then skyrocketed by 389.38% in 2021.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Receivables - Other stood at $113,000 in 2020, then skyrocketed by 389.38% to $553,000 in 2021, then skyrocketed by 144.67% to $1.4 million in 2022, then soared by 125.50% to $3.1 million in 2023, then spiked by 172.37% to $8.3 million in 2024.